Radiolabeled Peptides and Proteins in Cancer Therapy

Title: Radiolabeled Peptides and Proteins in Cancer Therapy

Volume: 14 Issue: 3

Author(s): Carmen Wangler, Inga Buchmann, Michael Eisenhut, Uwe Haberkorn and Walter Mier

Affiliation:

Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting

Abstract: With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.

Cite this article as:

Wangler Carmen, Buchmann Inga, Eisenhut Michael, Haberkorn Uwe and Mier Walter, Radiolabeled Peptides and Proteins in Cancer Therapy, Protein & Peptide Letters 2007; 14 (3) . https://dx.doi.org/10.2174/092986607780090874